Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors

Cell chemical biology(2022)10.1016/j.chembiol.2022.11.006Source: DataRank Database

Allosteric regulation of DNA binding and target residence time drive the cytotoxicity of phthalazinone-based PARP-1 inhibitors is a research paper published in Cell chemical biology (2022). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

11 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 0.74)OA: closedTopics (35)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Marie-France Langelier ORCID,Jessica Gartrell ORCID,Ilsa T. Kirby ORCID,Daniel J. Sanderson ORCID,Daniel S. Bejan ORCID

Live enrichment

PubMed:36493759 OpenAlex:https://openalex.org/W4312018465

National Institute of Neurological Disorders and Stroke

Grant: 2R01NS088629

National Institute of Neurological Disorders and Stroke

Grant: Pip6

NIH

Grant: P30NS061800

NIH

Grant: P30CA065823

CSC – IT Center for Science

Grant: 2000461

Canadian Institutes of Health Research

Grant: PJT173370

Canadian Institutes of Health Research

Grant: unidentified

unidentified

Biocenter Finland

Sarcoma Foundation of America

St. Baldrick's Foundation

Sigrid Juséliuksen Säätiö

Oregon Health and Science University

PEW Charitable Trusts

Magyar Tudományos Akadémia

AstraZeneca

FWCI

0.74

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

2026

closedLicense: Elsevier Non-Commercial

publisherhttps://api.elsevier.com/content/article/PII:S2451945622004123?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451945622004123?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.chembiol.2022.11.006

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36493759

repositoryhttp://www.scopus.com/inward/record.url?scp=85143883117&partnerID=8YFLogxK

Fields of Study

PARP inhibition in cancer therapyIntegrated Circuits and Semiconductor Failure AnalysisDNA Repair Mechanisms0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsAllosteric RegulationAntineoplastic AgentsBinding SitesNAD

Keywords

Allosteric regulationCytotoxicityPoly ADP ribose polymeraseNAD+ kinasePARP inhibitorDNAChemistryDNA replicationBinding siteBiochemistryBiologyCell biologyStereochemistryIn vitroEnzymePolymeraseAdp-ribosylationParpsTarget Residence TimeNad(+)-competitive InhibitorsBinding SitesAntineoplastic AgentsPoly(ADP-ribose) Polymerase InhibitorsNAD

Sustainable Development Goals

SDG 0: Good health and well-being